Evaluation of Short-term Efficacy of Neoadjuvant Chemotherapy and Pathological Changes in Patients with Advanced Breast Cancer by DWI

doi:10.7517/issn.1674-0475.190919

Abstract

Abstract: In this study, to investigate the correlation between the result of diffusion weighted imaging (DWI) and neoadjuvant chemotherapy in locally advanced breast cancer, and to provide the imaging basis for the prognosis of locally advanced breast cancer, 72 patients with advanced breast cancer who underwent neoadjuvant chemotherapy in our hospital from February 2016 to February 2017 were divided into effective group and ineffective group according to the curative effect of chemotherapy. And patients were also divided into non-major histological response (NMHR) group and major histological response (MHR) group according to the pathological reactivity. Then the values of ADC before and after treatment were compared, and the correlation between tumor volume reduction and ADC value was analyzed. In 72 cases of advanced breast cancer patients treated with neoadjuvant chemotherapy, the treatment were effective in 45 cases. The effective rate is 62.50% (45/72), and the ineffectiveness rate was 37.50% (27/72). After the chemotherapy, there were 43 cases of MHR and 29 cases of NMHR. The tumor volume in the effective group was significantly smaller than that in the ineffective group, and the tumor volume in the MHR group was significantly smaller than that in the NMHR group (P<0.05). The ADC value of the four groups before treatment showed no significant difference (P>0.05), and were all increased after treatment. Moreover, the ADC value of effective group and MHR group were higher than that in the ineffective group and NMHR group respectively (P<0.05). The added ADC value between groups showed a significant difference (P<0.05). Tumor volume was negatively correlated with ADC value, and tumor volume reduction value was positively correlated with the ADC added value. This study showed that the ADC value of DWI was negatively correlated with the tumor volume in patients with advanced breast cancer, which can effectively evaluate the short-term efficacy and pathological changes of neoadjuvant chemotherapy.

Key words: DWI, locally advanced breast cancer, neoadjuvant chemotherapy, efficacy, correlation

CLC Number:

TONG Ying, MI Nan, ZHANG Rong, XING Qianchao, YANG Yueyun, WANG Shenglin. Evaluation of Short-term Efficacy of Neoadjuvant Chemotherapy and Pathological Changes in Patients with Advanced Breast Cancer by DWI[J]. Imaging Science and Photochemistry, 2020, 38(2): 307-312.

References

[1] 郑莹, 吴春晓, 张敏璐. 乳腺癌在中国的流行状况和疾病特征[J]. 中国癌症杂志, 2013,23(8):561-569. Zheng Y, Wu C X, Zhang M L. The prevalence and disease characteristics of breast cancer in China[J]. Chinese Journal of Cancer, 2013,23(8):561-569.
[2] Ogino K, Nakajima M, Kakuta M, et al. Utility of FDG-PET/CT in the evaluation of the response of locally advanced breast cancer to neoadjuvant chemotherapy[J]. International Surgery, 2014,99(4):309-318.
[3] 沈璐, 唐菲, 林翌, 等. 磁共振扩散加权成像ADC值对局部进展期乳腺癌新辅助化疗疗效及病理反应性的评估价值[J]. 临床和实验医学杂志, 2017,16(7):717-720. Shen L, Tang F, Lin Y, et al. The value of MR diffusion-weighted imaging ADC in evaluating the efficacy and patholo-gic response of neoadjuvant chemotherapy for locally advanced breast cancer[J]. Journal of Clinical and Experimental Medicine, 2017,16(7):717-720.
[4] 牛昀. 2012年版《WHO乳腺肿瘤分类》新变化与临床治疗的关系[J]. 中华乳腺病杂志(电子版), 2014,8(3):1-5. Niu Y. The relationship between the new changes of the WHO version of WHO breast tumor classification and clinical treatment in 2012[J]. Chinese Journal of Breast Diseases, 2014,8(3):1-5.
[5] Ogston K N, Miller I D, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J]. Breast, 2003,12(5):320-327.
[6] 郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. Zheng R S, Sun K X, Zhang S W, et al. Report of cancer epidemiology in China, 2015[J].Chinese Journal of Oncology, 2019,41(1):19-28.
[7] Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients[J].Journal of Breast Cancer, 2014,17(4):376-385.
[8] Maforo N, Li H, Lan L, et al. SU-F-R-26:prognostic radiomics of breast cancer on DCE and DWI MR images[J]. Medical Physics, 2016,43(6Part6):3378-3378.
[9] 赵娓娓, 全志永, 陈燕, 等. DWI及ADC值在胃癌淋巴结性质判断及化疗疗效评估中的作用[J]. 放射学实践, 2015,30(5):566-570. Zhao W W, Quan Z Y, Chen Y, et al. The role of DWI and ADC values in the judgment of lymph node properties and eva-luation of chemotherapy efficacy in gastric cancer[J]. Radio-logy Practice, 2015,30(5):566-570.
[10] 朱振国, 姜熳. 核磁共振全身弥散加权成像(WB-DWI)在乳腺癌患者术前化疗疗效评估中的应用价值[J]. 肿瘤学杂志, 2016,22(6):443-447. Zhu Z G, Jiang M. The value of whole body diffusion-weighted imaging (WB-DWI) in the evaluation of preoperative chemotherapy in breast cancer patients[J].Journal of Oncology, 2016,22(6):443-447.
[11] 李向阳, 刘灵灵, 倪毅. 乳腺癌1.5T MRI动态增强扫描及DWI与免疫组化指标相关性分析[J]. 中国CT和MRI杂志, 2017,15(9):37-39. Li X Y, Liu L L, Ni Y. Dynamic contrast-enhanced scan of breast cancer with 1.5T MRI and correlation analysis between DWI and immunohistochemical markers[J]. Chinese Journal of CT and MRI, 2017,15(9):37-39.
[12] Kong D, Wang M H, Jie Y, et al. Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Oncotarget, 2017,8(8):13747-13753.
[13] 宋萌萌, 张天月, 王丽君, 等. IVIM多参数预
[1] 测乳腺癌免疫组化指标表达的可行性研究[J]. 磁共振成像, 2017,8(3):170-175. Song M M, Zhang T Y, Wang L J, et al. Feasibility study of IVIM multi-parameter pre-
[1] measurement of breast cancer immunohistochemical markers[J]. Magnetic Resonance Imaging, 2017,8(3):170-175.
[14] 薛彩霞, 邱传亚, 张勇, 等. DWI和Vibrant动态增强MR成像在乳腺癌中的诊断价值[J]. 放射学实践, 2014,29(1):61-63. Xue C X, Qiu C Y, Zhang Y, et al. Diagnostic value of DWI and Vibrant dynamic enhanced MR imaging in breast cancer[J]. Radiology Practice, 2014,29(1):61-63.
[15] Debled M, Macgrogan G, Breton-Callu C, et al. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude[J].European Journal of Cancer, 2015,51(6):697-704.